- Home
- GFL vs BBIO Comparison
GFL vs BBIO Comparison
Compare GFL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GFL | BBIO |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 15.9B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GFL | BBIO |
|---|---|---|
| Price | $42.42 | $65.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 22 |
| Target Price | $50.52 | ★ $109.05 |
| AVG Volume (30 Days) | 2.8M | ★ 2.8M |
| Earning Date | 10-28-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $21.66 | $104.49 |
| Revenue Next Year | $21.95 | $65.30 |
| P/E Ratio | $5.95 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $33.33 | $52.75 |
| 52 Week High | $47.01 | $93.42 |
Technical Indicators
Market Signals| Indicator | GFL | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 36.60 |
| Support Level | $42.08 | $63.22 |
| Resistance Level | $44.95 | $70.37 |
| Average True Range (ATR) | 0.99 | 2.09 |
| MACD | 0.03 | 0.34 |
| Stochastic Oscillator | 78.88 | 31.43 |
Price Performance
Historical ComparisonAbout GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.